The Filing Desk

NeoGenomics Laboratories vs Pennant Group

NeoGenomics Laboratories NEO · Pennant Group PNTG · Health Care Services

Pennant Group reported revenue of $948 million in fiscal 2025, 1.3 times NeoGenomics Laboratories' $727 million in fiscal 2025. NeoGenomics Laboratories' revenue grew 10.1% in its latest year, and Pennant Group's grew 36.3%. NeoGenomics Laboratories had an operating margin of -15.9%, against 5.5% at Pennant Group. Free cash flow was −$22 million at NeoGenomics Laboratories and $36 million at Pennant Group.

Side by side

NeoGenomics LaboratoriesPennant Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$727M$948M
Revenue growth10.1%36.3%
Revenue growth a year, last 5 years10.4%19.4%
Gross margin43.2%—
Operating margin−15.9%5.5%
Net margin−14.8%3.1%
Free cash flow−$22M$36M
Free cash flow margin−3.0%3.8%
Return on capital−8.8%9.3%
Net debt to EBITDA—2.6x
Dividends and buybacks$0M$0M
Change in diluted share count1.1%10.4%
Last close$16.02$36.07
P/E at the last close—36.1×
Insider trades, last 12 monthssold $967,816sold $690,087
Piotroski F-score5 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NeoGenomics LaboratoriesPennant Group
Operating margin
Percent of revenue
NeoGenomics LaboratoriesPennant Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeoGenomics LaboratoriesPennant Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NeoGenomics Laboratories and Pennant Group pages.